Navigation Links
Novavax Reports Second Quarter 2009 Financial Results
Date:8/7/2009

other comprehensive income related to the recovery of fair value for four of the securities.

The net decrease in cash and short-term investments of $2.7 million was principally due to cash spent for operations and cash paid for principal and interest totaling $12.1 million related to the retirement of $17.0 million of convertible debt, which were partially offset by net proceeds from the sale of common stock to Cadila of $10.7 million and proceeds from the sale of stock under the ATM program of $14.0 million. Novavax believes that based on the balance of cash and short-term investments at June 30, 2009, along with the proceeds from its transaction with ROVI of $3.0 million and the proceeds of $8.0 million received from additional sales of stock under the ATM program in July 2009, it has sufficient funds to execute its current business plan for at least the next twelve months. Novavax may pursue additional funding through the potential sale of equity securities, other non-dilutive financing, or additional partnering agreements, as opportunities arise.

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Conference Call

Novavax's management will host its quarterly conference call at 10:00 a.m. Eastern time (7:00 a.m. Pacific time) today. The live conference call will be accessible via Novavax's website at www.novavax.com under Investor/Events or by tele
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
2. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
4. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
5. Novavax Announces Repayment of $5 Million of Convertible Debt
6. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
7. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
8. Novavax Appoints Stanley Erck to Board of Directors
9. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
10. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
11. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Materials in Society Lecture Series at   ...   Elsevier , a world-leading provider of ... home of Materials Today , announced that its ... in Society  Lecture Series . The inaugural lectures ... Conference on Materials for Advanced Technologies (ICMAT) to be ...
(Date:3/31/2015)... March 31, 2015  The Myeloma Crowd Research Initiative ... of ten proposals that will now be evaluated ... patient-led, scientifically validated funding initiative uncovering solutions for ... of the MCRI included preliminary vetting by the ... large number of innovative projects focusing on high-risk ...
(Date:3/31/2015)... Diasome Pharmaceuticals, Inc. ( http://www.diasome.com ) has ... United States patent has recently been allowed for the ... Entitled “Lipid Construct for Delivery of Insulin to a ... to the use of Diasome’s proprietary Hepatocyte Directed Vesicles ... more effectively reach the liver’s metabolic cells, called hepatocytes. ...
(Date:3/30/2015)... Struggles (Nasdaq: HSII ), the premier provider of ... shaping worldwide, today  announced that John Mitchell ... Life Sciences practice. As Global Practice Managing Partner ... of more than 80 partners, principals and associates in the ... serving clients in the biopharmaceutical, medical technology and ...
Breaking Biology Technology:Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 2Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 3Myeloma Crowd Research Initiative Selects 10 High-Risk Multiple Myeloma Proposals For Further Review 2Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2
... Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) announced today that ... on the progress of,Sangamo,s ZFP Therapeutic development programs and ... (ET) on Tuesday, August 5, 2008,at the BMO Capital ... The presentation will be webcast live and may ...
... AMRIX Off to Strong Starts ... to 2009 Maintains 2008 Earnings Guidance Despite New Spending for Pre-Launch ... Activity and Increased AMRIX Investment, FRAZER, Pa., July 29 Cephalon, ... sales of $435.2 million for the second quarter 2007 and the company,s,sales ...
... to Emergent,s breaches ... FDA ... Conn., July 29 Protein Sciences Corporation,("PSC") announced today that the ... Emergent BioSolutions, Inc. (NYSE: EBS ),and its affiliate (collectively "Emergent") ...
Cached Biology Technology:Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference 2Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008 2Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008 3Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008 4Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008 5Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008 6Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008 7Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008 8Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008 9Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008 10Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008 11Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008 12Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008 13Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008 14Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008 15Protein Sciences Announces Termination of Deal to Sell to Emergent BioSolutions 2
(Date:3/17/2015)... 17, 2015  MecklerMedia Corporation (OTCQX: MECK) announced ... service robots ever held in New ... May 11-13, 2015 at the Javits Convention Center. ... event include: Acorn Product Development; Axis NJ; c-Link ... Robotics; Littler; NewBotic Corporation; Neya Systems LLC; Reliabotics; ...
(Date:3/12/2015)... N.C. , March 12, 2015 The ... at Brenner Children,s Hospital, part of Wake Forest Baptist ... outreach initiative for the 2015 ACC Men,s Basketball Tournament. ... pictures with them and getting their autographs. ... Forest Baptist. It is the only children,s hospital in ...
(Date:3/11/2015)... , Mar. 11, 2015 Research and Markets ... of the "Access Control Market by Product, Application ... 2020" report to their offering. , ... expected to reach $10.4 billion by 2020, with an ... market report covers the products types such as contact ...
Breaking Biology News(10 mins):MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2
... has been named one of five national Centers ... gene and cell therapies for inherited diseases affecting ... Digestive and Kidney Diseases, one of 19 National ... million grant for Cincinnati Children,s to establish the ...
... ESA is pleased to announce the winners of its ... Plenary Session of the ESA Annual Meeting in San Diego, ... be presented on Tuesday, December 14, 8:00-9:00 p.m. The awardees ... acknowledges those who have served ESA for at least 20 ...
... PHILADELPHIA Researchers at Kaiser Permanente have found that patients ... in situ or DCIS) who have higher mammographic density may ... the breast opposite to the one with the initial cancer. ... Epidemiology, Biomarkers & Prevention , a journal of the American ...
Cached Biology News:NIH funds Center of Excellence for Molecular Hematology at Cincinnati Children's 2NIH funds Center of Excellence for Molecular Hematology at Cincinnati Children's 3Entomological Society of America names 2010 Insect Science Award winners 2Entomological Society of America names 2010 Insect Science Award winners 3Entomological Society of America names 2010 Insect Science Award winners 4Entomological Society of America names 2010 Insect Science Award winners 5Entomological Society of America names 2010 Insect Science Award winners 6Entomological Society of America names 2010 Insect Science Award winners 7Entomological Society of America names 2010 Insect Science Award winners 8Entomological Society of America names 2010 Insect Science Award winners 9Entomological Society of America names 2010 Insect Science Award winners 10Entomological Society of America names 2010 Insect Science Award winners 11Entomological Society of America names 2010 Insect Science Award winners 12Entomological Society of America names 2010 Insect Science Award winners 13Entomological Society of America names 2010 Insect Science Award winners 14Entomological Society of America names 2010 Insect Science Award winners 15Breast density linked to increased risk of subsequent breast cancer 2
...
Mouse monoclonal [7A6] to NFAT2 ( Abpromise for all tested applications). entrezGeneID: 4772 SwissProtID: O95644...
Carbonate-Bicarbonate Buffer Capsules. For use in coating ELISA plates. Dissolve contents of 1 capsule in 100 ml deionized water to yield 0.05 M carbonate-bicarbonate buffer, pH 9.6....
...
Biology Products: